trending Market Intelligence /marketintelligence/en/news-insights/trending/7nh_cvqffbj53mmibc0m4w2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Veracyte nets $55.1M from common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Veracyte nets $55.1M from common stock offering

Veracyte, Inc. closed its public offering of common stock with about $55.1 million in net proceeds.

The South San Francisco, Calif.-based molecular diagnostics company offered 5,750,000 shares at $10.25 apiece, which included 750,000 shares bought by the underwriters after they fully exercised their option to buy additional shares.

Veracyte intends to use the net proceeds for working capital and other general corporate purposes. The company may also use the funds for potential acquisitions.

Leerink Partners and William Blair acted as joint book-running managers, while BTIG served as lead manager for the offering.